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Introduction
Currently, the most effective curative treatment approach
for patients with myelodysplastic syndromes (MDS) or sec-
ondary acute myeloid leukemia (sAML) evolving from MDS
is allogeneic stem cell transplantation (SCT).1 With the intro-
duction of reduced intensity conditioning (RIC), the non-
relapse mortality (NRM) could be lowered, especially in older
patients.2,3 However, disease relapse is the most important
factor for long-term overall survival (OS) after SCT in patients
surviving the (acute) treatment-related toxicity.4 Besides stage
of the disease (e.g. number of marrow blasts, time from diag-
nosis to transplant, prior chemotherapeutic treatment and
remission status), the karyotype of the disease seems to be
most predictive for relapse-free survival (RFS) after transplan-
tation.5-15 However, most studies used the International
Prognostic Scoring System (IPSS) cytogenetic risk score (good,
intermediate, and poor cytogenetic risk groups) for the analy-
sis of relapse and OS after SCT in MDS patients.16 In 2012, a
new 5-group cytogenetic scoring system with a refined cyto-
genetic risk prediction in MDS patients not undergoing SCT
was proposed.17 This scoring system includes clonal abnor-
malities, which have been underrepresented in the IPSS cyto-
genetic risk score categories. Therefore, the 5-group cytoge-
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The aim of this study was to determine the impact of the revised 5-group International Prognostic Scoring System
cytogenetic classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic
syndromes or secondary acute myeloid leukemia who were reported to the European Society for Blood and
Marrow Transplantation database. A total of 903 patients had sufficient cytogenetic information available at stem
cell transplantation to be classified according to the 5-group classification. Poor and very poor risk according to
this classification was an independent predictor of shorter relapse-free survival (hazard ratio 1.40 and 2.14), overall
survival (hazard ratio 1.38 and 2.14), and significantly higher cumulative incidence of relapse (hazard ratio 1.64
and 2.76), compared to patients with very good, good or intermediate risk. When comparing the predictive per-
formance of a series of Cox models both for relapse-free survival and for overall survival, a model with simplified
5-group cytogenetics (merging very good, good and intermediate cytogenetics) performed best. Furthermore,
monosomal karyotype is an additional negative predictor for outcome within patients of the poor, but not the
very poor risk group of the 5-group classification. The revised International Prognostic Scoring System cytogenetic
classification allows patients with myelodysplastic syndromes to be separated into three groups with clearly dif-
ferent outcomes after stem cell transplantation. Poor and very poor risk cytogenetics were strong predictors of
poor patient outcome. The new cytogenetic classification added value to prediction of patient outcome compared
to prediction models using only traditional risk factors or the 3-group International Prognostic Scoring System
cytogenetic classification.  
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ABSTRACT
netic risk classification entered the revised IPSS (IPSS-R)
scoring system for patients with MDS, which was
renewed in 2012 accordingly.18
The impact of the revised IPSS-R for MDS patients
undergoing SCT was analyzed in one single center study,13
and more recently in a national multicenter study.14 These
studies have shown that the novel classification has
greater discriminating power for OS and relapse after SCT
than the old IPSS classification. In contrast to the latter
studies, we focused only on cytogenetic information of
the novel 5-group IPSS-R classification to evaluate the out-
come of MDS and sAML patients after SCT in an analysis
based on a large cohort from the European Society for
Blood and Marrow Transplantation (EBMT) database. The
analysis was performed using the latest available kary-
otype before transplantation, restricted to measurements
within one year before SCT.
In addition to previous findings13,14 which also focus on
IPSS-R cytogenetics and SCT, we show that poor and very
poor risk cytogenetics, within the IPSS-R-cytogenetic risk
categories, are strong predictors of poor outcome after
transplantation, also when other risk factors are consid-
ered simultaneously. Furthermore, the presence of a
monosomal karyotype (MK) has an additional impact on
RFS and OS, but only in the poor risk group and not in the
very poor risk cytogenetics group of patients.
Methods
Patients with MDS or sAML with available cytogenetic infor-
mation within 12 months before transplantation and an HLA-
matched donor were identified from the EBMT-database.
Cytogenetic information, as reported to the database, was
reviewed and classified according to MK, IPSS16 and IPSS-R.18
Patients who received more than one allograft were kept in the
analysis and the outcome of the first SCT was used. Base-line
information, transplant-characteristics and follow-up information
of patients were down-loaded from the database.
Definition of disease status at SCT
Disease status at SCT was defined according to the FAB19 or
WHO classification,20 to remission status and to prior chemother-
apy. These definitions led to 4 patient groups: 1) patients with
refractory anemia (RA), RA with ringsideroblasts (RARS) or refrac-
tory cytopenias with multilineage dysplasia (RCMD) who had
never had higher MDS-stages (RA with excess of blasts, RAEB;
chronic myelomonocytic leukemia, CMML, sAML) and who did
not receive chemotherapy before SCT; 2) RAEB or RAEB in trans-
formation (RAEB(t))/sAML/CMML without induction chemother-
apy and, therefore, not in remission; 3) RAEB or
RAEB(t)/sAML/CMML with induction chemotherapy leading to
complete remission (CR); 4) RAEB or RAEB(t)/sAML/CMML with
refractory disease or relapse after induction chemotherapy. 
We did not include percentage of bone marrow blasts in our
analysis since our definition of patient groups contains this infor-
mation. Patients who received hypomethylating agents were con-
sidered as patients without chemotherapy, since statistical com-
parison showed that there was no difference between outcomes
of RAEB(t)/sAML/CMML patients in CR respectively not in CR
after treatment with hypomethylating agents and outcomes of
patients in CR respectively not in CR who did not receive
hypomethylating agents (data not shown). Less than 5% of all
patients had CMML.
Statistical analysis
The primary end point for this analysis was RFS, defined as the
time from transplantation to death or disease progression, with
surviving patients censored at the last time point reported alive
and disease-free.21 OS was defined as the time from SCT to death,
with surviving patients censored at the last time point reported
alive. Cumulative incidence of relapse (CIR) was defined as time
from transplantation to disease progression. Non-relapse mortality
(NRM) was defined as time from transplantation to death before
disease progression. RFS and OS were analyzed in stratified
Kaplan-Meier curves, comparing outcomes for different groups by
means of two-sided log ranks tests. Similarly, CIR and NRM were
analyzed by means of cumulative incidence curves, testing for dif-
ferences by means of the Gray test.22 
The impact of cytogenetic classifications in combination with
other risk factors was assessed in multivariate Cox regression
models for RFS and OS. Results of these analyses were used to cre-
ate simplified versions of the classifications. Model fit of multivari-
ate models for each outcome was compared by means of the
Akaike information criterion (AIC). Predictive performance of
models was compared by means of the cross-validated log partial
likelihood.23 
Explorative analyses of competing risks outcomes were made in
multivariate Cox models for cause-specific hazards, including as
predictors those selected in the OS and RFS models.
Software used was SPSS 20 (IBM SPSS Statistics) and R 3.0.2
(http://www.r-project.org/), with ‘survival’,24 ‘cmprsk’22 and ‘dyn-
pred’25 libraries.
Results
Patients’, disease and transplant characteristics at SCT
In total, 3265 MDS or sAML patients with cytogenetic informa-
tion were reported to the EBMT-database from 1981 to 2012. Of
IPSS-R cytogenetics after transplantation for MDS
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Table 1. Patients’ and disease characteristics of MDS/sAML patients
(n=903).
                                                                                         N. (%)
Patient age (years)                                                                               
Median (range)                                                                         50.0 (18-74)
Patient sex*                                                                                            
Male                                                                                               500 (55.4)
Female                                                                                           402 (44.6)
Disease status at transplant**                                                          
RA/RARS/RCMD without treatment                                         97 (10.7)
RAEB/sAML/CMML in CR                                                          218 (24.1)
RAEB/sAML/CMML not in CR                                                   250 (27.7)
RAEB/sAML/CMML untreated                                                  227 (25.1)
Cytogenetic risk (IPSS, 3-group)                                                       
Good                                                                                               192 (21.3)
Intermediate                                                                                500 (55.4)
Poor                                                                                                211 (23.4)
Cytogenetic risk (IPSS-R, 5-group)                                                  
Very good                                                                                        19 (2.1)
Good                                                                                               204 (22.6)
Intermediate                                                                                438 (48.5)
Poor                                                                                                178 (19.7)
Very poor                                                                                         64 (7.1)
*Missing in one patient. **Unknown in 111 patients.
those, 2569 patients had cytogenetic information dated within one
year before SCT. Despite the rather short interval from karyotypic
information to transplantation in most patients, there might be a
number of patients for whom the cytogenetic information has
changed during that time. Patients were excluded because of insuf-
ficient cytogenetic information for reliable classification into the 5-
group IPSS-R classification, missing essential information on fol-
low up after SCT, recent year of SCT (2011-2012), age below 18
years, treatment-related AML, unknown, syngeneic or mis-
matched donor, or cord blood graft. The remaining patients were
included in the study. These patients received SCT for the treat-
ment of MDS or sAML between 1982 and 2010. At time of SCT,
97 (11%) patients had untreated RA/RARS/RCMD, 250 patients
(28%) had untreated advanced MDS or AML evolving from MDS,
218 (24%) patients had advanced MDS or sAML in CR, and 227
(25%) patients were not in remission after treatment (in 12%
information was not available). Median time between diagnosis
and transplant was 6.6 months (range 0.2-359.3 months). Matched
related donor SCT was performed in 574 patients (64%), and
matched unrelated donor SCT in 329 patients (36%). Bone mar-
row (35%) or peripheral blood (65%) served as stem cell graft. A
total of 582 patients (65%) received myeloablative preparative reg-
imens, whereas a non-myeloablative regimen was given to 320
patients (35%). Details on disease and patients’ characteristics, as
well as the transplant procedure, are shown in Tables 1 and 2.
Reclassification of 3-group-IPSS into 5-group-IPSS-R
cytogenetic classification
According to the 5-group cytogenetic IPSS-R classification 19
(2%) patients had very good risk cytogenetics, 204 (23%) good
risk cytogenetics, 438 (48%) intermediate risk cytogenetics, 178
(20%) poor risk cytogenetics, and 64 (7%) very poor risk cytoge-
netics. 
Comparing the 3-group-IPSS cytogenetic classification with the
more recent 5-group IPSS-R cytogenetic classification, patients
were re-distributed as follows: 9 patients (5%) of the good risk
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402 haematologica | 2015; 100(3)
Table 2. Transplant characteristics of MDS/sAML patients (n=903).
                                                                                      N. (%)
Donor type                                                                                          
Matched related                                                                      574 (63.6)
Matched unrelated                                                                 329 (36.4)
Stem cell source                                                                                
PBSC                                                                                           583 (64.6)
Bone marrow                                                                           320 (35.4)
Conditioning*                                                                                     
Myeloablative                                                                           582 (64.5)
Reduced intensity                                                                   320 (35.4)
Recipient-donor sex match**                                                        
Female donor for male recipient                                        164 (18.2)
All other combinations                                                          733 (81.2)
CMV Ig G of recipient and donor***                                            
Negative/negative                                                                   224 (24.8)
Negative/positive                                                                      96 (10.6)
Positive/negative                                                                     185 (20.5)
Positive/positive                                                                      281 (31.1)
*Missing in one patient. **Missing in 6 patients. ***Unknown in 117 patients.  RA:
refractory anemia; RARS:  refractory anemia with ringsideroblasts; RAEB:  refractory ane-
mia with excess of blasts; RCMD:  refractory cytopenia with multilineage dysplasia;
sAML:  secondary acute myeloid leukemia; CMML:  chronic myelomonocytic leukemia;
CR: complete remission; IPSS:  International Prognostic Scoring System; PBSC:  periph-
eral blood stem cells; Ig:  Immunoglobulin; CMV: cytomegalovirus.
Table 3. Univariate analysis for RFS, OS, CIR and NRM in MDS and
sAML patients. Outcomes at 60 months after SCT are based on
Kaplan-Meier estimates for RFS and OS and on Cumulative Incidence
estimates for CIR and NRM. P-values are derived from the 2-sided log-
ranks test (RFS and OS) and from the Gray test (CIR and NRM), both
tests comparing the entire curves up to 60 months. 
Variables N. % RFS OS CIR NRM
(%) (%) (%) (%)
All patients 903 100 32 36 36 33
Age
18-40 262 29 35 40 31 34
40-50 186 21 37 41 31 32
50-60 291 32 29 33 39 32
>60 164 18 24 27 44 33
P - - 0.050 0.096 0.018 0.819
Disease status at SCT
RA/RARS/RCMD untreated
RAEB(t)/sAML/CMML in CR 97 11 54 57 12 34
RAEB(t)/sAML/CMML 218 24 37 41 40 24
untreated 227 25 34 39 29 38
RAEB(t)/sAML/CMML 250 28 18 22 48 34
not in CR - - <0.001 <0.001 <0.001 0.008
P
3-group IPSS-cytogenetics
Good 192 21 36 40 29 35
Intermediate 500 55 34 40 36 30
Poor 211 23 21 24 42 37
P - - <0.001 <0.001 0.020 0.076
5-group IPSS-R-cytogenetics
Very Good 19 2 42 58 30 28
Good 204 23 36 40 30 34
Intermediate 438 49 36 41 34 31
Poor 178 20 22 27 42 36
Very poor 64 7 10 11 56 34
P - - <0.001 <0.001 <0.00 0.588
Donor
Matched related 574 64 32 37 38 30
Matched unrelated 329 36 30 34 33 37
P - - 0.388 0.134 0.197 0.041
Graft
Bone marrow 320 35 31 35 30 38
Peripheral blood stem cells 583 65 31 37 39 29
P - - 0.193 0.109 0.018 0.001
Conditioning
Myeloablative 582 64 33 38 32 34
Reduced intensity 320 35 29 33 42 29
P - - 0.141 0.717 <0.001 0.097
Recipient-donor sex match
Female donor for male patient 164 18 25 30 32 42
All other combinations 733 81 33 37 37 30
P - - 0.095 0.072 0.285 0.005
CMV status (recipient/donor)
-/- 224 29 34 40 38 28
-/+ 96 12 32 37 38 30
+/+ 281 36 34 39 35 31
+/- 185 24 33 35 27 39
P - - 0.957 0.585 0.161 0.139
Year of SCT
1982-1999 272 30 33 36 30 37
2000-2006 323 36 30 35 39 30
2007-2010 308 34 17 32 48 35
P - - 0.380 0.259 0.05 0.098
OS: overall survival; RFS: relapse-free survival; CIR: cumulative incidence of relapse;
NRM: non-relapse mortality; HR: hazard ratio; CR: complete remission; MRD: matched
related donor; MUD: matched unrelated donor; SCT: stem cell transplantation; CMV:
cytomegalovirus.
group became very good risk in the 5-group classification, and 183
patients (95%) remained in the good risk group also in the new
classification; the intermediate risk group patients were re-
grouped into very good (n=10, 2%), good risk (n=21, 4%) and
poor risk (n=31, 6%); 438 patients (88%) remained in the interme-
diate risk group; 64 patients (44%) of the poor risk group were re-
grouped into the very poor risk group according to the new classi-
fication; this was proportionally the largest shift within all risk
groups (Figure 1).
Outcome analysis 
The primary goal of this analysis was to determine RFS after
SCT according to the recent 5-group IPSS-R cytogenetic classifica-
tion and to investigate the added value of the new classification-
compared to the old for predicting this outcome. We hypothe-
sized that what has been shown for cytogenetic risk profiles and
outcome of MDS patients not undergoing SCT17 in terms of dis-
ease progression is also true for transplant patients at time of SCT.
Univariate analysis
Median follow up of patients alive was 60 months after SCT
(taking into account artificial censoring at 60 months). The esti-
mated 5-year RFS in all patients was 32%. 5-group cytogenetic
IPSS-R information was found to be significantly associated with
RFS in univariate analysis (P<0.001). RFS was 42% in very good
and 36% in good risk patients, 36% in intermediate, 22% in poor
and 10% in very poor risk patients at 5 years (Figure 2A).
Since relapse after transplantation is frequently fatal because of
limited treatment options, this directly affects OS, which is the
secondary end point of our analysis. OS in all patients was 36% at
five years after SCT. As expected, 5-group IPSS-R cytogenetic
information was also strongly associated with OS (OS: log rank
test P<0.001). The OS in very good risk patients was 58%, 40% in
good risk, 41% in intermediate, 27% in poor and 11% in very
poor risk patients after five years (Figure 2B).
Disease status at SCT (RA/RARS/RCMD no pre-treatment;
RAEB(t)/sAML/CMML in CR; RAEB(t)/sAML/CMML not in CR,
RAEB(t)/sAML/CMML untreated) was a predictor for RFS and OS
(OS: P<0.001, RFS: P<0.001). Higher patient age was predictive for
lower RFS (P=0.05), but not for OS (P=0.09) in univariate analyses.
Furthermore, the year of SCT was not associated with RFS
(P=0.38) or OS (P=0.26).
Whether a matched donor was related or unrelated did not sig-
nificantly affect either RFS (P=0.39) or OS (P=0.13). Similarly, the
donor graft, bone marrow or peripheral blood stem cells, did not
influence RFS or OS in this cohort of patients (RFS P=0.19, OS
P=0.11), neither did the conditioning regimen (RFS P=0.14, OS
P=0.72). The combination of CMV status of patients and donors
(RFS P=0.96, OS P=0.59) or a female donor for a male recipient
(RFS P=0.09, OS P=0.07) were not significant predictors for RFS or
OS in univariate analysis. The type of conditioning regimen
(reduced or standard) did not significantly affect outcome (RFS
P=0.14, OS P=0.72) (Table 3).
Multivariate analysis
The goal of the multivariate analysis was to identify the risk fac-
tors with best predictive value for RFS and OS with a focus on
cytogenetic information. We first built models for RFS and OS
including potentially relevant predictors on the basis of results
from the literature but excluding cytogenetics (Online
Supplementary Table S1). The most predictive variables were select-
ed by means of a back-step selection procedure (excluding covari-
ates associated with P>0.1 in the conditional statistic). The propor-
tionality assumption was checked for all variables in this reduced
model. The model was then extended by adding the 3-group IPSS-
cytogenetic classification as a relevant predictor for outcome.
Since the Hazard Ratio for intermediate risk patients in the 3-
group IPSS model (with respect to good risk patients) was close to
1 (data not shown), the model was simplified by combining good
IPSS-R cytogenetics after transplantation for MDS
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Figure 1. Re-grouping of patients from IPSS cytogenetic subgroups
(good/ intermediate/ poor) into new IPSS-R cytogenetic subgroups
(very poor/ poor/ intermediate/ good/ very good). Numbers in the
diagram indicate absolute numbers of patients.
Figure 2. Kaplan-Meier curves of relapse-free (A) and overall (B) sur-
vival of MDS/sAML patients after allogeneic stem cell transplanta-
tion according to 5-group cytogenetic risk classification.
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and intermediate risk patients into one “standard-group” category
(Online Supplementary Table S2).
To test whether the recent 5-group cytogenetic classification is
most predictive for outcome, we replaced the simplified 3-group
cytogenetic with the 5-group IPSS-R-classification in a fourth Cox
regression model (data not shown). Similarly to what we observed
for the 3-group IPSS-classification in the second model, the HRs
for good risk patients and for intermediate risk patients (both with
respect to very good risk patients) were close to 1. Therefore, the
model was simplified by combining very good, good and interme-
diate risk patients into one “standard-group” category. A compari-
son of these two models by means of AIC and the cross-validated
log partial likelihood showed that the simplified model had better
model fit and predictive performance. Patients with poor risk (RFS:
HR=1.40; OS: HR=1.38) or very poor risk cytogenetic category
(RFS: HR=2.14; OS: HR=2.14) had worse RFS and OS than
patients in the other (merged) standard group (Table 4). It is wor-
thy of note that an additional Cox model showed that T-cell
depletion during conditioning therapy did not significantly
increase relapse risk (data not shown).
When comparing the predictive performance of all five models
(1=risk factors without cytogenetic information, 2=+3-group IPSS-
cytogenetic classification, 3=+simplified 3-group IPSS-cytogenetic
classification, 4=+5-group-IPSS-R-cytogenetic classicification,
5=+simplified 5-group-IPSS-R cytogenetic classification) both for
RFS and OS, according to AIC and cross-validated log partial like-
lihood, the model with simplified 5-group IPSS-R risk classifica-
tion performed best for predicting outcomes after SCT. AIC scores
for the RFS models were 7261.3, 7245.5, 7243.5, 7240.0, 7236.1,
respectively. This shows that the new classification improves out-
come prediction for patients at SCT (Figure 3).
Impact of monosomal karyotype
Next, we analyzed the value of MK as a predictor for RFS and
OS. In the multivariate models, the presence of MK did not
improve the prediction of RFS or OS (Online Supplementary Table
S3). Since most patients who harbor MK are grouped into the poor
and very poor risk cytogenetic IPSS-R classification, we performed
a subgroup analysis of these patients, categorizing them into 4
groups based on MK versus no MK and very poor versus poor risk.
Interestingly, MK has an additional impact on prediction of RFS
(P<0.001) and OS (P=0.001), but only in the poor risk group (RFS:
P=0.003; OS: P=0.004; log rank test for poor risk patients only) but
not in the very poor risk group (RFS: P=0.61; OS: P=0.71, log rank
test for poor risk patients only). RFS at five years was 27% in poor
risk patients without MK and only 9% in poor risk patients with
MK. In patients of the very poor risk group the RFS was 12%
without and 4% with MK at five years (Figure 4).
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Figure 3. Kaplan-Meier curves of relapse-free (A) and overall (B) sur-
vival of MDS/sAML patients after allogeneic stem cell transplanta-
tion according to the simplified 5-group cytogenetic risk classifica-
tion.
Figure 4. Kaplan-Meier curves of relapse-free (A) and overall (B) sur-
vival of MDS/sAML patients with poor and very poor cytogenetic risk
with and without monosomal karyotype (MK).
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Non-relapse mortality and cumulative incidence 
of relapse
We evaluated the impact of IPSS-R cytogenetic category on the
cumulative incidence of relapse (CIR) and non-relapse mortality
(NRM). CIR was significantly higher in patients with poor and
very poor risk cytogenetics compared to the “standard-group” (5-
year CIR 42% and 56% vs. 34%, respectively; P<0.001), while
NRM was similar in these cytogenetic risk groups (5-year NRM
36% and 34% vs. 31%, respectively; P=0.59) (Figure 5).
Next, we investigated cause-specific hazards for CIR and NRM
in a Cox regression model that included the simplified 5-group
IPSS-R cytogenetic classification. In this model, age over 60 years
(HR=1.99, P<0.001), disease status at SCT (RAEB/sAML/CMML
in CR, HR=3.64, P<0.001; RAEB/sAML/CMML untreated,
HR=2.84, P=0.001; RAEB/sAML/CMML treated not in CR,
HR=6.17, P<0.001), poor (HR=1.64, P=0.001) and very poor
(HR=2.76, P<0.001) cytogenetic risk classification were adverse
risk factors for relapse. The very poor risk cytogenetic group was
also associated with a high NRM (HR=1.60, P=0.046) (Table 5).
Outcome of re-classified patients
Finally, we compared the outcome of re-classified patients.
Patients from the IPSS poor risk cytogenetic group distributed into
poor (n=147) and very poor (n=64) IPSS-R cytogenetic risk groups.
Thirty-one patients from the IPSS-intermediate risk group re-dis-
tributed into the poor risk IPSS-R-cytogenetic risk category (Figure
1). The outcome of re-classified very poor risk (from the IPSS poor
risk group) and poor risk patients (from IPSS intermediate risk
group) was very similar (RFS, P=0.35; OS, P=0.14), but worse than
for the other patients in the IPSS-R poor risk group (RFS, P=0.011;
IPSS-R cytogenetics after transplantation for MDS
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Table 4. Cox regression models with simplified 5-group IPSS-R cytogenetic classification for RFS and OS in MDS and sAML patients.
RFS OS
HR 95% CI P HR 95% CI P
Donor (matched unrelated vs.matched related) - - 1.25 1.03-1.52 0.028
Age 0.001 0.002
18-40 1.0 - 1.0 -
40-50* 0.98 0.76-1.25 0.860 1.04 0.80-1.35 0.769
50-60* 1.14 0.91-1.43 0.252 1.23 0.97-1.56 0.083
>60* 1.62 1.24-2.13 <0.001 1.70 1.27-2.25 <0.001
Disease status at SCT** <0.001 <0.001
RA/RARS/RCMD untreated 1.0 - 1.0 -
RAEB/sAML/CMML in CR* 1.49 1.05-2.11 0.025 1.39 0.97-2.00 0.076
RAEB/sAML/CMML untreated* 1.69 1.20-2.37 0.003 1.60 1.12-2.28 0.010
RAEB/sAML/CMML treated, not in CR* 2.52 1.81-3.52 <0.001 2.30 1.62-3.24 <0.001
5-group IPSS-cytogenetics <0.00 <0.00
Standard§ 1.0 - 1.0 -
Poor* 1.40 1.15-1.71 0.001 1.38 1.12-1.70 0.003
Very poor* 2.14 1.60-2.86 <0.001 2.14 1.59-2.87 <0.001
Year of SCT 0.98 0.96-0.99 0.002 0.97 0.95-0.98 <0.001
*Compared to the first group (reference group) listed in each category. **Patients with missing data for disease status at SCT were kept in the analysis by assigning them to a sep-
arate category (HRs not shown). §Standard: merged very good, good and intermediate risk patients. OS: overall survival; RFS: relapse-free survival; HR: hazard ratio; CI: confidence
interval; IPSS: International Prognostic Scoring System; CR: complete remission; SCT: allogeneic stem cell transplantation.
Table 5. Cox regression models for cause-specific hazards for relapse and non-relapse mortality in MDS and sAML patients.
CIR NRM
HR 95%CI P HR 95%CI P
Donor (matched unrelated vs.matched related) 0.85 0.65-1.11 0.229 1.48 1.13-1.94 0.005
Age 0.001 0.394
18-40 1.0 - 1.0 -
40-50* 0.99 0.70-1.42 0.971 1.00 0.71-1.41 0.988
50-60* 1.23 0.90-1.70 0.197 1.09 0.79-1.50 0.604
>60* 1.99 1.37-2.90 <0.001 1.37 0.92-2.03 0.117
Disease status at SCT** <0.001 0.022
RA/RARS/RCMD untreated 1.0 - 1.0 -
RAEB/sAML/CMML in CR* 3.64 1.93-6.86 <0.001 0.76 0.49-1.19 0.235
RAEB/sAML/CMML untreated* 2.84 1.49-5.40 0.001 1.28 0.85-1.93 0.236
RAEB/sAML/CMML treated, not in CR* 6.17 3.31-11.51 <0.001 1.32 0.88-2.00 0.185
5-group IPSS-cytogenetics <0.001 0.090
Standard§ 1.0 - 1.0 -
Poor* 1.64 1.24-2.16 0.001 1.19 0.89-1.60 0.232
Very poor* 2.76 1.89-4.02 <0.001 1.60 1.01-2.53 0.046
Year of SCT 0.99 0.96-1.01 0.248 0.96 0.94-0.98 <0.001
*Compared to the first group (reference group) listed in each category. **Patients with missing data for disease status at SCT were kept in the analysis by assigning them to a sep-
arate category (HRs not shown).  §Standard: merged very good, good and intermediate risk patients. CIR: cumulative incidence of relapse; NRM: non-relapse mortality; HR: hazard
ratio; CI: confidence interval; IPSS: International Prognostic Scoring System; CR: complete remission; SCT: allogeneic stem cell transplantation.  
OS, P=0.026). The RFS at five years of the patients re-classified
from intermediate to poor was 6% and the OS was 13%.
Interestingly, of those 31 patients who were re-classified from IPSS
intermediate cytogenetic risk group into the poor risk group of the
IPSS-R-cytogenetic classification, 30 patients harbored a chromo-
some 3 aberration (data not shown).
Discussion
In this large, international, multicenter study, we clearly show
that the recent 5-group cytogenetic IPSS-R classification added
value in the prediction of patient outcome after SCT in MDS and
sAML patients compared to prediction models with only tradi-
tional risk factors or the 3-group IPSS-cytogenetic classification.
Patients with poor risk (RFS: HR=1.40; OS: HR=1.38) or very poor
risk cytogenetic category (RFS: HR=2.14; OS: HR=2.14) had worse
RFS and OS than patients in the other (merged) three risk groups.
Interestingly, MK is an additional negative predictor for outcome
within patients of the poor, but not the very poor risk group of the
5-group classification. Furthermore, age over 60 years and
advanced disease stages (RAEB(t)/sAML/CMML in CR,
RAEB(t)/sAML/CMML untreated and RAEB(t)/sAML/CMML not
in CR) were significant negative predictors for RFS and OS when
statistically tested in multivariate analyses in this retrospective
EBMT registry study.
These results are in line with previous reports showing an inde-
pendent association of the status of the disease6,7 and patient age3
with outcome after SCT. The cytogenetic information of the dis-
ease had been shown earlier to be a predictor of relapse or disease
progression in patients with MDS and sAML undergoing10-14,26 or
not undergoing27,28 SCT.
However, the main focus of this study was to analyze the
impact of cytogenetic information using the 5-group cytogenetic
IPSS-R information on RFS after SCT, since this information is of
major importance in defining post-transplant strategies for the pre-
vention of relapse. Nowadays, several post-transplant strategies
are available to handle impending disease relapse. Besides acceler-
ated tapering of immunosuppressive therapy and administration
of adjuvant donor leukocyte infusions (aDLI) to achieve graft-ver-
sus-tumor effects,29 the use of epigenetic modifiers in these
patients seems to be a therapeutic option.30 
In order to achieve robust results in this study, we included only
matched donors (related and unrelated) and only patients receiv-
ing either BM or PBSC as a stem cell graft (no cord blood grafts).
Due to the lack of high-resolution human leukocyte antigen-typ-
ing data in the majority of the cohort, we were only able to report
on 6/6 matched donor and recipients pairs. Only in recent years
have we been able to report on 10/10 matched donor and recipient
pairs. This might lead to heterogeneous groups of analyzed
patients and is, therefore, a potential limitation of our study. We
were very strict in selecting patients with available cytogenetic
information. More than 72% of MDS patients (n=2373) reported
to the EBMT database were excluded from the study due to insuf-
ficient and implausible cytogenetic reports or because of cytoge-
netic information which was acquired more than one year before
SCT. 
Interestingly, similar to other studies,13,14 we detected a differen-
tial prognostic value for RFS and OS after transplantation for very
poor and poor risk patients according to the new IPSS-R-cytoge-
netic classification, but in contrast to these, not for very good,
good and intermediate risk groups. We checked whether the cyto-
genetic information influenced the outcome to the same extent
comparing lower (RA/RARS/RCMD) with higher MDS stages
(RAEB/sAML/CMML) and we could not detect a significant differ-
ence (data not shown).
We also observed similar results when we used the old IPSS 
3-group cytogenetic classification, where only the poor risk group
was associated with worse patient outcome after allogeneic trans-
plantation, whereas good and intermediate risk groups had shown
no significant difference on survival.
Of note, when comparing the predictive performance of a series
of five models both for RFS and for OS, the model with simplified
IPSS-R cytogenetics and classical risk factors had the best predic-
tive performance, indicating the distinction between very good,
good and intermediate risk patients has no added value in the con-
text of predicting outcome after SCT. Patients in the poor risk
(RFS: HR=1.40; OS: HR=1.38) or very poor risk cytogenetic cate-
gory according to the IPSS-R classification (RFS: HR=2.14; OS:
HR=2.14) had worse RFS and OS than patients in the other
(merged) standard group (Table 4).
Therefore, the new IPSS-R cytogenetic scoring system improves
outcome prediction for MDS/sAML patients after SCT. In contrast
to the old 3-group IPSS classification, we can now separate
patients not only into two (poor and merged others), but also into
three patient groups with clearly different outcomes (very poor,
poor and merged others). Additionally we could show that the
presence of MK in the poor, but not the very poor risk group pre-
dicted worse outcome. Therefore, poor and very poor risk cytoge-
netic information in combination with MK in patients with MDS
or sAML is of major importance for the clinician to decide on post-
transplant treatment strategies in terms of immunological or phar-
macological interventions.
When we analyzed the patients who were re-grouped from the
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Figure 5. (A) Estimated cumulative incidence of relapse (CIR) and (B)
non-relapse mortality (NRM) according to simplified 5-group IPSS-R
cytogenetic risk groups until five years after SCT based on compet-
ing risks analysis.
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old into the new IPSS-R cytogenetic classification we observed
that these patients had a rather bad outcome in terms of RFS. We
noticed that, especially for the patients re-classifying from the
intermediate into the poor risk category, 30 of 31 patients har-
bored chromosome 3 aberrations. It is known that chromosome 3
aberrations lead to activation of EVI1 expression, which in turn
drives leukemogenesis.31 One could, therefore, speculate that
especially chromosome 3 aberrations enable the underlying dis-
ease to escape GvT effects after SCT. Hence, chromosome 3 aber-
rations are specifically important in the setting of transplantation
and new treatment strategies need to be established. In general,
somatic mutations such as ASXL1, EVI1 or TP53 in MDS patients
might be important predictors for outcome after SCT, similar to
what has been shown for patients not undergoing SCT.32
The predictive value of cytogenetic information for outcome
after allogeneic SCT has been reported by others, not only for the
3-group-IPSSclassification,33 but also for the 5-group IPSS-R-classi-
fication.13-15 In all studies, unfavorable cytogenetic information, as
classified according to the IPSS or IPSS-R classification, predicted
worse patient outcome. However, this study is the first to evaluate
formally the added value of the 5-group IPSS-R classification com-
pared to the 3-group classification in the setting of SCT for predic-
tive performance and to show that the relevant distinction in cat-
egories in this context is standard-poor-very poor when other risk
factors are taken into account. Furthermore, all disease-related
variables used for outcome prediction are assessed within one
year before transplantation and not at first diagnosis of MDS or
start of remission-induction chemotherapy, thus avoiding poten-
tial bias caused by correlation between timing of assessments and
their values. Since our study is to the best of our knowledge the
largest study dealing with this topic so far, we were also able to
include even a considerable number of very good risk patients.
Due to the multinational character of this study, center effects,
which occur due to differences in clinical practice, are expected to
be well balanced.
To gain information on the best transplant strategy in patients
with different cytogenetic risk groups, we compared outcome of
each single IPSS-R-cytogenetic risk group in relation to reduced or
standard conditioning (data not shown). In this analysis, we could
not detect a benefit of one of the two conditioning strategies for
any of the risk groups. Similarly, we could not detect any differ-
ence regarding RFS or OS in relation to T-cell depleting treatment
during conditioning therapy. However, and this is a clear weak-
ness of this retrospective registry based study, we had no complete
information on co-morbidities in most patients. It is rather clear
that the clinicians’ choice for the conditioning regimen frequently
depends on these co-morbidities, and only in younger patients
with few or no co-morbidities on the disease characteristics.
Therefore, this result has to be taken with caution.
In conclusion, this study clearly shows that poor and very poor
risk cytogenetic characteristics independently predicted worse
patient outcome after SCT in MDS and sAML patients. The pres-
ence of MK within the poor risk group of patients gives additional
information regarding outcome. Pre- and post-transplant strategies
to prevent relapse after allogeneic transplantation in these groups
of patients are of major importance.
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